Following a resubmission, the Canadian pERC has recommended the funding of pazopanib hydrochloride (Votrient) as a first-line treatment of patients with advanced or metastatic clear renal cell carcinoma and good performance status.  For more details, go to: http://www.pcodr.ca/idc/groups/pcodr/documents/pcodrdocument/pcodr-votrientmrccre-fn-rec.pdf